Dr. Ali Khaki on managing toxicities with enfortumab vedotin for bladder cancer


Ali Raza Khaki, MD, genitourinary specialist, clinical assistant professor, Medicine – Oncology, Stanford Medicine, discusses managing toxicities to ensure patients can continue to receive treatment with the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev). Khaki shared this information with his colleagues at a recent clinical workshop.

Enfortumab vedotin is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy; or patients who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.

Related Videos
Abstract blur luxury hospital corridor | Image Credit: @ zephyr_p - @ zephyr_p - stock.adobe.com
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Dr. Joshua Meeks in an interview with Urology Times
Alexander I. Sankin, MD, and Ahmed A. Aboumohamed, MD, answer questions during a video interview
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.